Context for Phibro Animal Health’s Recent Share Performance

Phibro Animal Health (PAHC) has seen mixed share performance recently, with the stock up about 29% over the past year but down around 8% over the past month and roughly 40% over the past 3 months.

Against this backdrop, Phibro’s latest reported figures show revenue of about US$1.5b and net income of roughly US$95.2m, with annual revenue growth around 3% and net income growth near 15%. These figures give investors a clearer sense of the current business scale.

At a share price of US$31.53, Phibro’s recent share price return has cooled in the short term. The 30 day move is down 8.26% and the 90 day move is down 39.95%, even as the 1 year total shareholder return sits at 29.21% and the 3 year total shareholder return is very large at about 2.4x. This suggests longer term holders have seen much stronger momentum than recent traders.

If Phibro’s recent pullback has you thinking about where else to put fresh capital to work, this can be a good moment to scan 38 healthcare AI stocks

So with Phibro trading at US$31.53 alongside revenue of about US$1.5b and net income near US$95.2m, is the recent pullback an undervaluation, or is the market already pricing in future growth?

Most Popular Narrative: 30.9% Undervalued

Phibro Animal Health’s most followed narrative points to a fair value of about $45.60, which sits well above the recent close of $31.53, and frames the current pullback as a valuation gap built on detailed revenue, margin and risk assumptions.

The company's strong recent growth is heavily dependent on the integration of the acquired Zoetis Medicated Feed Additive business and related cost synergies, which are non-repeatable, forward guidance suggests legacy product growth will slow to flat or low single digits, implying the current trajectory of accelerating revenue and EBITDA growth is unsustainable and likely to normalize, impacting revenue and earnings growth expectations.

Want to see what keeps that fair value near the $45 mark? The narrative leans on steady top line progress, healthier margins and a future earnings multiple that still sits below the sector. If you are curious which assumptions really carry the weight in those forecasts and how the 7.1% discount rate shapes the outcome, the full breakdown connects those moving parts directly to that $45.60 figure.

Result: Fair Value of $45.60 (UNDERVALUED)

However, the story could change if regulatory pressure on medicated feed additives intensifies, or if environmental policies meaningfully curb livestock herds and demand for animal health products.

Next Steps

Does this mix of risks and rewards feel balanced enough for you, or skewed one way? Act quickly, review the details carefully, and consider the 4 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Phibro has sharpened your interest, do not stop here. Widen your scope with a few targeted stock ideas that match different portfolio goals.

• Target potential mispricings by reviewing companies that screen as 43 high quality undervalued stocks with solid fundamentals and room for further research.
• Strengthen your income stream by focusing on dependable payers in the 8 dividend fortresses that already offer elevated yields.
• Prioritize capital preservation by researching companies in the 68 resilient stocks with low risk scores that score well on financial resilience and volatility.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.